This review is a report on the Re-Circuit study on uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. The study was conducted in 11 countries across 104 sites and involved almost 700 participants.
Independent commentary is provided by Dr Bradley Wilsmore a staff specialist in cardiology specialising in electrophysiology and conjoint lecturer (University of Newcastle).
Please login below to download this issue (PDF)